SILVER SPRING
FDA approves oveporexton for narcolepsy type 1
- Sponsor
- Takeda Pharmaceuticals $TAK
- Drug
- oveporexton
- Indication
- narcolepsy type 1
FDA approved Takeda Pharmaceuticals's oveporexton (oveporexton) for narcolepsy type 1 on 2026-08-05.
What this means
Oveporexton is a new drug for narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness. Today the FDA approved it for use in patients with this disorder. This provides a new treatment option for managing these disruptive symptoms.